Research


   Home

  Technology Platform

  Biopharmaceutical

Biomarkers

-Molecular Binding

-Receptor and Ligand

-RNA Interference

-High-throughput Screening

-High-content Screening

Biotechnology

Biodefense

Bioinformatics


Mail

  Biomarkers

 

  
By carefully designing clinical studies which compare proteins in body fluid samples from patients suffering from a disease with samples from members of a control group who do not have that disease, we are able to identify protein bio-markers for that disease. Bio-markers are proteins that are present in a disease state and can be observed or measured in order to determine the efficacy of a drug or the status of the disease. Present use of bio-markers is largely focused on the analysis of a single chosen protein. Our industrial-scale proteomics technology allows us to identify both individual proteins, as well as small clusters of proteins, which we believe provide more specific information than can typically be obtained today using a single protein for analysis.

The collection and analysis of samples of tissues and body fluids, such as serum, urine, saliva and CSF, from patients with major diseases is an important element of what we do. Our ability to work with human tissues increases the chances of discovering potential new protein targets, and our ability to work with human body fluids increases the chances of discovering potential new protein bio-markers.

Examples of uses of proteins as bio-markers include:

1. Enabling diseases to be diagnosed earlier and with a higher degree of accuracy,

2. Identifying a population of patients who might be expected to benefit from a particular drug and distinguishing this group from other patients who may be less likely to respond to the same drug, and

3. Measuring the response of a patient's disease to a drug treatment.

We believe that bio-markers can be used to give an early indication of a drug candidate's efficacy and safety during clinical trials, leading to more efficient drug development. Measuring bio-markers may also lead to new diagnostic tests.

 

 

 
Pharmacom Corporation Copyright 1997-2007